Center of Excellence in Higher Education
The First Private University in Bangladesh

Dr. Abdullah-Al Masum

 

Full Time Faculty
Assistant Professor

Ph.D., Tokyo University of Science, Japan
M.Pharm, Tokyo University of Science, Japan

Phone: +880-2-55668200 Ext: 6403
Email: abdullah.masum01@northsouth.edu
Office: SAC1057

Curriculum Vitae

 

 

 
 

Dr. Abdullah-Al Masum graduated from Jahangirnagar University. After his graduation, he worked in Pharmaceuticals companies for several years. Meanwhile, he got the Japan government scholarship (Monbukagakusho/MEXT) to continue higher studies in Japan. He completed Master of Pharmaceutical Sciences from the Tokyo University of Science and Ph.D. specialization in cancer drug design and synthesis, from the same university.

Tumor necrosis factor related apoptosis inducing ligand (TRAIL) is a cytokine classified in TNF superfamily that triggers apoptosis in a wide variety of cancer cells by complexation with death receptors (DR4 and DR5). TRAIL is a C3-symmetric protein consist of three monomeric units. Cyclometalated iridium (III) complexes such as fac-Ir(tpy)3 (tpy = 2-(4-tolyl)pyridine have excellent luminescent properties and possess C3-symmetric structure like TRAIL. Therefore, Ir complexes having DR binding motifs are expected to mimic the TRAIL to induce cancer cell apoptosis and detect cancer cells.

During Ph.D. course, Dr. Abdullah-Al Masum has designed and synthesized some molecules based on luminescent iridium complexes conjugated with DR5 binding peptide. The Ir complex-peptide conjugates are capable of binding with DR5 and detecting cancer cells such as Jurkat, K562 and Molt-4 cells. One of the conjugates binds with DR5 and initiates cell-extrinsic apoptosis signaling to induce cancer cell apoptosis. Another conjugates bind with DR5 and internalize into cell cytoplasm via receptor-mediated endocytosis and induce necrosis in cancer cells. Ir complex-peptide conjugates are the first example of chemical agents that achieve imaging and cell death induction of cancer cells associated with DR5.

 
 

 Journal Publications

1. Masum, A.; Yokoi, K., Hisamatsu, Y.; Naito, K., Shashni, B., Aoki, S. Design and Synthesis of a Luminescent Iridium Complex-Peptide Hybrid (IPH) that Detects Cancer Cells and Induces Their Apoptosis. Bioorganic & Medicinal Chemistry. 2018; 26 (17): 4804-4816.

 

2. Masum, A.; Hisamatsu, Y.; Yokoi, K., Aoki, S. Luminescent Iridium Complex-Peptide Hybrids (IPHs) for Therapeutics of Cancer: Design and Synthesis of IPHs for Detection of Cancer Cells and Induction of Their Necrosis-type Cell Death. Bioinorganic Chemistry and Applications. 2018; Article ID: 7578965.

 

 3. Hisamatsu, Y.; Suzuki, N.; Masum, A.; Shibuya, A.; Abe. R.; Sato, A.; Tanuma, S.; Aoki, S.  Cationic Amphiphilic Tris-Cyclometalated Iridium(III) Complexes Induce Cancer Cell Death via Interaction with Ca2+-Calmodulin Complex. Bioconjugate Chem. 2017; 28 (2): 507–523.

 

Conference Publications

1. Masum, A.; Hisamatsu, Y.; Suzuki, N.; Aoki, S. Detection and Induction of Cell Death of Cancer Cells by Luminescent Iridium Complexes Having Death Receptor Binding Peptides. (Poster presentation). 17th Asian Chemical Congress (17ACC). July 23-28, 2017, Melbourne, Australia.

 

 2. Masum, A.; Hisamatsu, Y.; Suzuki, N.; Aoki, S. Detection and Induction of Cell Death of Cancer Cells by Luminescent Iridium Complex-Peptide Hybrids. (Oral presentation) 15th symposium on organic chemistry-the next generation. May 26-27, 2017, Tokyo, Japan.

 

 3. Masum, A.; Hisamatsu, Y.; Suzuki, N.; Aoki, S. Detection and Induction of Cell Death of Cancer Cells by Luminescent Iridium Complexes Having Death Receptor Binding Peptides. (Poster presentation) Annual meeting of Division of Medical-Science-Engineering Cooperation, Research Institute for Science and Technology, TUS. March 09, 2017, Chiba, Japan.

 

4. Masum, A.; Hisamatsu, Y.; Suzuki, N.; Aoki, S. Observation of Cell Death Signal of Cancer Cells by DR5 Binding Peptide-Iridium Complex Hybrids for selective Staining and Induction of Cell Death of Cancer Cells. (Poster presentation) Imaging Frontier Center Symposium. December 10, 2016, Chiba, Japan.

 

 5. Masum, A.; Hisamatsu, Y.; Suzuki, N.; Aoki, S. Design and Synthesis of DR5 Binding Iridium Complex-Peptide Hybrids for Selective Staining and Induction of Cell Death of Cancer Cells. (Oral presentation) 60th Annual Meeting of The Pharmaceutical Society of Japan (Kanto branch). September 17, 2016, Tokyo, Japan.

 

6. Masum, A.; Hisamatsu, Y.; Suzuki, N.; Aoki, S. Design and Synthesis of TRAIL Mimics Based on C3-symmetric and Luminescent Iridium Complexes that are Able to Stain and Induce Cell Death of Cancer Cells. (Oral presentation) 136th Annual Meeting of The Pharmaceutical Society of Japan. March 26-29, 2016, Yokohama, Japan.

 

7. Masum, A.; Hisamatsu, Y.; Suzuki, N.; Aoki, S. Design and Synthesis of Artificial TRAIL Mimics Based on C3-symmetric and Luminescent Iridium Complexes that are Able to Stain and Induce Cell Death of Cancer Cells.  (Oral presentation) International Postgraduate Conference on Pharmaceutical Science (iPoPS2016). Feb 27-28, 2016, Chiba, Japan.

 

8. Masum, A.; Tanaka, H., Suzuki, N., Hisamatsu, Y.; Aoki, S. Design and Synthesis of Artificial TRAIL Mimics Based on C3-symmetric and Luminescent Iridium Complexes. (Poster presentation) International Chemical Congress of Pacific Basin Societies. December 15-20, 2015, Honolulu, Hawaii, U.S.A.

 

9. Masum, A.; Koinuma, K.; Miyata, Y.; Hisamatsu, Y.; Aoki, S. Design and Synthesis of Artificial Death Ligands Based on Metal-Centered Homotrimeric Self-Assembly of Chelator-Peptide Hybrids. (Poster presentation) 134th Annual Meeting of The Pharmaceutical Society of Japan. March 27-30, 2013, Kumamoto, Japan.

  • Japan Government (Monbukagakusho) Scholarship (October 2012 to March 2018)
  • Winner of oral presentation award, International Postgraduate Conference on Pharmaceutical Sciences (iPoPs2016)

 

 Ph.D. in Pharmaceutical Sciences (2015-2018)

Tokyo University of Science, Tokyo, Japan

CGPA: 4/4

 

Master of Pharmaceutical Sciences (2013-2015)

Tokyo University of Science, Tokyo, Japan

CGPA: 3.75/4

 

Bachelor of Pharmaceutical Sciences (2002-2006)    

Jahangirnagar University, Dhaka, Bangladesh

First class

  • Assistant Professor, Department of Pharmaceutical Sciences, North South University. December 18, 2018, to till date
  • Teaching Assistant at the Tokyo University of Science
  • Senior Product Executive, Apex Pharma Ltd. Dhaka, Bangladesh. May 08, 2011, to August 31, 2012
  • Product Executive, Orion Pharma Ltd. Dhaka, Bangladesh. September 01, 2008, to May 06, 2011
  • Training Executive, Silva Pharmaceuticals Ltd. Dhaka, Bangladesh. May 03, 2008, to August 31, 2008
 

 

  • Human Physiology I
  • Organic Pharmacy I
  • Organic Pharmacy II
  • Pharmacology and Clinical Pharmacy III
 
 

 

 

Research Interests:

Chemical Biology, Synthetic Bioorganic Chemistry, Biomedical Fluorescent Imaging, Cancer Research and Cancer Therapeutic Targets, Supramolecular Chemistry.

 

Research Expertise:

  • Cell Culture and Cell Assay
  • Fluorescence Microscopy
  • Confocal Microscopy
  • Flow Cytometry
  • Quartz Crystal Microbalance
  • Organic Synthesis
  • Purification technique:

                             Column Chromatography

                             High-Performance Liquid Chromatography (HPLC)

                             Gel Phase Chromatography (GPC)

                             Recrystallization

                             Separation and Extraction

  • Spectroscopy (UV/Vis, NMR, IR, Mass)
  • Fluorescence spectroscopy (quantum yield, lifetime measurement)
  • Other software:

                     Imaris (3D Image Analysis Software) 

                     Flowjo (Flow Cytometry Analysis Software)

                     Discovery Studio

                     Chem Office (ultra)

                     Affinix Q4